MeSH D000080424 - cytokine release syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D018746:Systemic inflammatory response syndrome
0 Companies
0 Drugs
Success rate
D000080424:
Cytokine release syndrome
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Biogen | Tocilizumab | Tofidence | 2023-09-29 | |||
| Fresenius Kabi | Tocilizumab | Tyenne | 2023-09-15 | |||
| Genentech | Tocilizumab | Actemra | 2010-01-08 | |||
| Roche | Tocilizumab | RoActemra | 2009-01-15 |
Clinical Trials
Historical Success Rate
Phase 1
50%1/2
Phase 2
42%8/19
Phase 3
33%2/6
Approved: 1Overall Success rate: 7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use